ecancermedicalscience · 2018 · 56 citations · 16 references
PharmacyOncologyChemotherapyOutcomes ResearchPalliative MedicineCancer Burden AssessmentChemotherapy Toxicity ManagementHealthcare Cost AnalysisPatient-reported Outcome MeasuresToxicity GradingToxicity ManagementCancer Cost BurdenEconomic Burden Of CancerFinancial Toxicity RiskInternal Consistency ReliabilityPatient Financial Burden AnalysisPatient-reported Toxicity GradingQuality Of Life EndpointsUtility Measurement In Oncology
BACKGROUND: Financial toxicity (FT) has a negative impact on the quality of life and survival of patients with cancer. The comprehensive score for FT (COST) questionnaire is a tool to measure FT which has already been validated in patients with cancer in the United States. However, the feasibility and validity of assessing FT using the COST questionnaire have not been established in non-US healthcare settings, including that in Japan. METHODS: This is a prospective pilot survey to ascertain the feasibility of using the COST questionnaire to evaluate FT in Japanese patients with advanced solid cancer who had been receiving chemotherapy for at least 2 months. The COST questionnaire was translated into Japanese using Functional Assessment of Chronic Illness Therapy methodology. RESULTS: of 0.87. CONCLUSIONS: The COST measure demonstrated good feasibility in measuring FT in the Japanese healthcare setting. Despite the existing universal health insurance system and ceiling amount for high-cost medical expenses, some Japanese patients experienced meaningful FT during chemotherapy. A prospective study is already underway to confirm the preliminary results (UMIN: 000025043).
16
The development of a financial toxicity patient‐reported outcome in cancer: The COST measure
Jonas A. de Souza, Bonnie J. Yap, Fay J. Hlubocky et al. · Cancer · 2014 · 649 citations · Full text